Free Trial

Protagonist Therapeutics (PTGX) News Today

$36.20
+0.65 (+1.83%)
(As of 01:40 PM ET)
Protagonist Therapeutics logo with Medical background
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by BNP Paribas Financial Markets
BNP Paribas Financial Markets cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 34.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 47,233 shares of the company's stock after selling 24,665
Protagonist Therapeutics logo with Medical background
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Sees Significant Decline in Short Interest
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 2,040,000 shares, a decrease of 34.6% from the June 15th total of 3,120,000 shares. Based on an average trading volume of 860,800 shares, the days-to-cover ratio is presently 2.4 days.
Protagonist Therapeutics logo with Medical background
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High at $35.99
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 52-Week High at $35.99
Protagonist Therapeutics logo with Medical background
GSA Capital Partners LLP Has $1.60 Million Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
GSA Capital Partners LLP increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 179.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,359 shares of the company's stock after purcha
Protagonist Therapeutics logo with Medical background
Protagonist Therapeutics (NASDAQ:PTGX) Sees Strong Trading Volume
Protagonist Therapeutics (NASDAQ:PTGX) Sees Large Volume Increase
Financial markets news icon
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024
Stocks that are trading heavily or have substantial price changes on Friday: Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise
Protagonist Therapeutics logo with Medical background
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up to $31.88
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up to $31.88
Protagonist Therapeutics (NASDAQ:PTGX) Shares Up 3.8%
Protagonist Therapeutics (NASDAQ:PTGX) Shares Up 3.8%
Perceptive Advisors LLC Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Perceptive Advisors LLC cut its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 63.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 383,260 shares of the company's stock after selling 671,013 shares duri
Opaleye Management Inc. Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Opaleye Management Inc. bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 112,700 shares of the company
Protagonist Therapeutics (NASDAQ:PTGX) Receives "Buy" Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $38.00 target price on shares of Protagonist Therapeutics in a report on Friday.
ADAR1 Capital Management LLC Makes New $4.61 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
ADAR1 Capital Management LLC purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 200,859 shares of the company's stock,
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High at $35.69
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High at $35.69
Superstring Capital Management LP Invests $8.69 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Superstring Capital Management LP acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 379,143 shares of the company's stock
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 6%
Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 6%
Rafferty Asset Management LLC Sells 182,486 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Rafferty Asset Management LLC lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 52.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 167,795 shares of the company's stock after sel
RTW Investments LP Has $121.89 Million Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
RTW Investments LP decreased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,315,514 shares of the company's
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 1-Year High at $34.34
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High at $34.34
Protagonist Therapeutics (NASDAQ:PTGX) Shares Up 7.9%
Protagonist Therapeutics (NASDAQ:PTGX) Shares Up 7.9%
The 3 Best Biotech Stocks to Buy in June 2024
BNP Paribas Financial Markets Trims Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
BNP Paribas Financial Markets reduced its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 50.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,898 shares of the company's stock after sell
Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Great Lakes Advisors LLC
Great Lakes Advisors LLC cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,153 shares of the company's stoc
Gratus Capital LLC Has $9.12 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Gratus Capital LLC lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 397,571 shares of the com
Analysts Offer Predictions for Protagonist Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:PTGX)
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Protagonist Therapeutics in a research note issued on Thursday, May 9th. HC Wainwright analyst D. Tsao anticipates that the company will p
Protagonist Therapeutics' (PTGX) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $38.00 price target on shares of Protagonist Therapeutics in a report on Thursday.
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up to $25.79
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up to $25.79
Protagonist Therapeutics, Inc. (PTGX)
Insider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells 1,234 Shares of Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 1,234 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the transaction, the chief financial officer now directly owns 37,163 shares in the company, valued at approximately $933,162.93. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Readystate Asset Management LP Has $1.31 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Readystate Asset Management LP trimmed its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 69.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,206 shares of the company's stock after sellin
Vanguard Group Inc. Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Vanguard Group Inc. increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,228,394 shares of the company's stock after buying an additio
Protagonist Therapeutics Inc CEO Sells 25,000 Shares
Get Protagonist Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

REVEALED: The Top Hotspot Stock for this month! (Ad)

Most folks insist on overcomplicating their trading with fancy indicators or news headlines… But former hedge fund manager Roger Scott just waits for his new system to show him the “Hotspot Dates” on his favorite stocks. That means there’s a legitimate shot at targeting double or even triple-digit gains on these exact dates year after year. Check out what the research shows happened to Adobe this year during the “Hotspot Dates”...

Go here to get the top “Hotspot Stock” for this month

PTGX Media Mentions By Week

PTGX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PTGX
News Sentiment

0.51

0.58

Average
Medical
News Sentiment

PTGX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PTGX Articles
This Week

1

3

PTGX Articles
Average Week

Get Protagonist Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:PTGX) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners